tNOX (ENOX2) target for chemosensitization-low-dose responses in the hormetic concentration range

American Journal of Pharmacology and Toxicology

Volumn 3, Issue 1, 2008, Pages 16-26

  Morre, D James ^a   Dick, Sara ^b   Bosneaga, Elena ^a   Balicki, Andrew ^a   Wu, L Y ^b   McClain, Nicole ^a   Morre, Dorothy M ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cancer; Cisplatin; ECTO NOX; HeLa cells; NADH oxidase; Ovarian carcinoma; Paclitaxel; Phenoxodiol; Sulforaphane

Indexed keywords

CISPLATIN; ISOFLAVONE DERIVATIVE; PACLITAXEL; PHENOXODIOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SULFORAPHANE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIZATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; HORMESIS; HUMAN; HUMAN CELL; MONOTHERAPY; NUCLEOTIDE SEQUENCE; OVARY CANCER; UTERINE CERVIX CARCINOMA;

EID: 53049098890     PISSN: 15574962     EISSN: 15574970     Source Type: Journal    
DOI: 10.3844/ajptsp.2008.19.29     Document Type: Article

References (51)

1. Calabrese, E.J., 2007. Threshold dose-response model-RIP: 1911 to 2006. Bioessays, 29 (7): 686-688.
2. Southam, C.M. and J. Erlich, 1943. Effects of extracts of western red-cedar heartwood on certain wood-decaying fungi in culture. Phytopathology, 33: 517-524.
3. Calabrese, E.J. and L.A. Baldwin, 2001. The frequency of U-shaped dose-responses in the toxicological literature. Toxicol. Sci., 62: 330-338.
4. Calabrese, E.J. and L.A. Baldwin, 2003. Toxicology rethinks its central belief-Hormesis demands a reappraisal of the way risks are assessed. Nature, 421: 691-692.
5. Morré, D.J., l998. A protein disulfide-thiol interchange protein with NADH: protein disulfide reductase (NADH oxidase) activity as a molecular target for low levels of exposure to organic solvents. Human Exptl. Toxicol., l7: 272-277.
6. Morré. D.J., 2000. Chemical hormesis in cell growth: A molecular target at the cell surface. J. Appl. Toxicol., 20: 157-163.
7. Morré, D.J., 1998. In: Plasma Membrane Redox Systems and Their Role in Biological Stress and Disease. Asard, H., A. Bérczi and R.J. Caubergs, (Eds.). Kluwer Academic Publishers, Dordrecht, pp: 121-156.
8. Morré, D.J. and D.M. Morré, 2003. Cell surface NADH oxidases (ECTO-NOX proteins) with roles in cancer, cellular time-keeping, growth, aging and neurodegenerative diseases. Free Radic. Res., 37: 795-808.
9. Morré, D.J., P.J. Chueh and D.M. Morre, 1995. Capsaicin inhibits preferentially the NADH oxidase and growth of transformed cells in culture. Proc. Natl. Acad. Sci. USA, 92: 1831-1835.
10. Morré, D.J., C. Kim, M. Paulik, D.M. Morré and W.P. Faulk, 1997. Is the drug-responsive NADH oxidase of the cancer cell plasma membrane a molecular target for adriamycin? J. Bioenerg. Biomembr., 29: 269-280.
11. Morré, D.J., A. Bridge, L.Y. Wu and D.M. Morré, 2000. Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture. Biochem. Pharmacol., 60: 937-946.
12. Morré, D.J., L.Y. Wu and D.M. Morré, 1995. The antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl) urea (LY181984) inhibits NADH oxidase activity of HeLa plasma membranes. Biochim. Biophys. Acta, 1240: 11-17.
13. Morre, D.J., P.J. Chueh, K. Yagiz, A. Balicki, C. Kim and D. M. Morre, 2007. ECTO-NOX target for the anticancer isoflavene phenoxodiol. Oncol. Res., 16: 299-312.
14. Chueh, P.J., L.Y. Wu, D.M. Morre and D.J. Morré, 2004. tNOX is both necessary and sufficient as a cellular target for the anticancer actions of capsaicin and the green tea catechin (-)-epigallocatechin-3-gallate. BioFactors, 20:235-249.
15. Holmes, F.A., R.S. Walters, R.L. Theriault, A.D. Forman, L.K. Newton, M.N. Raber, A.U. Buzdar, D.K. Frye and G.N. Hortobagyi, 1991. Phase II trial of Paclitaxel, an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83: 1797-1805.
16. McGuire, W.P., E.K. Rowinsky, N.B. Rosenshein, F.C. Grumbine, D.S. Ettinger, D.K. Armstrong and R.C. Donehower, 1989. Paclitaxel: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Int. Med., 111 (4): 273-279.
17. Matsui, T.A., Y. Sowa, T. Yoshida, H. Murata, M. Horinaka, M.M. Wakada, R. Nakanishi, T. Sakabe, T. Kubo and T. Sakai, 2006. Sulforaphane enhanced TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis, 27: 1768-1777.
18. Mor, G., H.H. Fu and A.B. Alvero, 2006. Phenoxodiol, a novel approach for the treatment of ovarian cancer. Curr. Opin. Invest. Drugs, 7 (6): 542-548.
19. Morré, D.J., D. Sedlak, X. Tang, P.-J. Chueh, T. Geng and D.M. Morré, 2001. Surface NADH oxidase of HeLa cells lacks intrinsic membrane binding motifs. Arch. Biochem. Biophys., 392: 251-256.
20. del Castillo-Olivares, A., P.J. Chueh, S. Wang, M. Sweeting, F. Yantiri, D. Sedlak, D.J. Morre and D.M. Morré, 1998. A drug-responsive and protease-resistant peripheral NADH oxidase complex from the surface of HeLa S cells. Arch. Biochem. Biophys., 358: 125-140.
21. Morré, D.J., S. Caldwell, A. Mayorga, L.Y. Wu and D.M. Morr_aace, 1997. NADH oxidase activity from sera altered by capsaicin is widely distributed among cancer patients. Arch. Biochem. Biophys., 342: 224-230.
22. Morré, D.J. and T. Reust, 1997. A circulating form of NADH oxidase activity responsive to the antitumor sulfonylurea N-4-(methylphenylsulfonyl)-N′-(4-chlorophenyl) urea (LY181984) specific to sera from cancer patients. J. Bioenerg. Biomembr., 29: 281-289.
23. Cho, N., P.J. Chueh, C. Kim, S. Caldwell, D.M. Morré and D.J. Morré, 2002. Monoclonal antibody to a cancer-specific and drug-responsive hydroquinone (NADH) oxidase from the sera of cancer patients. Cancer Immunol. Immunother., 51: 121-129.
24. Chueh, P.J., C. Kim, N. Cho, D.M. Morré and D.J. Morré, 2002. Molecular cloning and characterization of a tumor-associated, growth-related and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry, 41: 3732-3741.
25. Bird, C., 1999. Direct submission of human DNA sequence from clone 875H3 (part of APK1 antigen) to GenBank database at NCBI. (Accession no. AL049733).
26. Morré, D.M. and D.J. Morré. 2006. Catechinvanilloid synergies with potential clinical applications in cancer. Rejuvination Res., 9: 45-55.
27. Morré, D.J., N. McClain, L.-Y. Wu, G. Kelly and D.M. Morré, Submitted. Phenoxodiol treatment alters the subsequent response of tNOX and growth of HeLa cells to paclitaxel and cisplatin. In vitro Cell Dev. Biol. Anim.
28. Morré, D.J., 1995. NADH oxidase activity of HeLa plasma membranes inhibited by the antitumor sulfonylurea N-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl) urea (LY181984) at an external site. Biochim. Biophys. Acta, 1240: 201-208.
29. Thejass, P. and G. Kuttan, 2006. Antimetastatic activity of sulforaphane. Life Sci., 78: 3043-3050.
30. Fimognari, C., M. Nusse, M. Lenzi, D. Scluscio, G. Cantelli-Forti and P. Prelia, 2006. Sulforaphane increases the efficacy of doxorubicin inmouse fibroblasts characterized by p53 mutations. Mutat. Res., 60: 92-101.
31. Kamsteeg, J., T. Rutherford, E. Sapi, B. Hanxzaruk, S. Shahabi, M. Flick, D. Brown and G. Mor, 2003. Phenoxodiol - an isoflavene analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene, 22: 2611-2620.
32. Brown, D.M., G. E. Kelly and A.J. Husband, 2005. Flavanoid compounds in maintenance of prostate health and prevention and treatment of cancer. Mol. Biotechnol., 30: 253-270.
33. Kelker, M., C. Kim, P.-J. Chueh, R. Guimont, D.M. Morré and D J. Morré, 2001. Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) has properties of a prion. Biochemistry, 40: 7351-7354.
34. Griffith, J.S., 1964. Self-replication and scrapie. Nature, 315: 1043-1044.
35. Prusiner, S.B., 1994. Biology and genetics of prion diseases. Annu. Rev. Microbiol., 48: 655-686.
36. Morré, D.J., D.M. Morré and P. Ternes, 2003. Auxin-activated NADH oxidase activity of soybean plasma membranes is distinct from the constitutive plasma membrane NADH oxidase and exhibits prion-like properties. In Vitro Cell Dev. Biol. - Plant, 39: 368-376.
37. Herst, P.M., T. Petersen, P. Jerram, J. Batty and M. Berridge, 2007. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem. Pharmacol., Epub. Aug. 19.
38. Rikiishi, H., F. Shinohara, T. Sato, Y. Sato, M. Suzuki and S. Echigo, 2007. Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid. Int. J. Oncol., 30(5): 1181-1188.
39. Sharma, H., S. Sen and N. Singh, 2005. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol. Ther., 4 (9): 949-955.
40. Li, M., Z. Zhang, D.L. Hill, H. Wang and R. Zhang, 2007. Curcumin, a dietary component, has anticancer, chemosensitization and radiosensitization effects by down-regulating the MDM2 oncogene through the PI3K/mTOR/ETS2 pathway. Cancer Res., 67 (5): 1988-1996.
41. Deeb, D.D., H. Jiang, X. Gao, G. Divine, S.A. Dulchavsky and S.C. Gautam, 2005. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J. Exp. Ther. Oncol., 5(2): 81-91.
42. Xin, Y., G. Lyness, D. Chen, S. Song, M.G. Wientjes and J.L. Au, 2005. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J. Urol., 174(1): 322-327.
43. Chen, G. and W.J. Zeller, 1991. Augmentation of cisplatin (DDP) cytotoxicity in vivo by DL-buthionine sulfoximine (BSO) in DDP-sensitive and-resistant rat ovarian tumors and its relation to DNA interstrand cross links. Anticancer Res., 11(6): 2231-2237.
44. Garg, A.K., T.A. Buchholz and B.B. Aggarwal, 2005. Chemosensitization and radiosensitization of tumors by plant polyphenols. Antioxid. Redox Signal., 7(11-12): 1630-1647.
45. Niu, J., X.N. Li, H. Qian and Z. Han, 2007. siRNA mediated the type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J. Cancer Res. Clin. Oncol., Sept. 28 (Epub ahead of print).
46. Fuessel, S., J. Herrmann, S. Ning, M. Kotzsch, K. Kraemer, U. Schmidt, O.W. Hakenberg, M.P. Wirth and A. Meye, 2006. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett., 232(2): 243-254.
47. Pu, Y.S., T.S. Hsieh, T.C. Tsai, A.L. Cheng, C.Y. Hsieh, I.J. Su and M.K. Lai, 1995. Tamoxifen enhances the chemosensitivity of bladder carcinoma cells. J. Urol., 154(2): 601-605.
48. Folmer, Y., M. Schneider, H.E. Blum and P.Hafkemeyer, 2007. Reversal of drug resistance of hepatocellular carcinoma cells by adenoviral delivery of anti-ABCC2 antisense constructs. Cancer Gene Ther., Aug 17 (Epub ahead of print).
49. Kim, Y.K., Y.J. Song, D.W. Seo, D.W. Kang, H.Y. Lee, D.K. Rhee, J.W. Han, C.M. Ahn, S. Lee and S.N. Kim, 2007. Reversal of multidrug resistance by 4-chloro-N-(3-((E)-3-(4-hydroxy-3-methoxyphenyl) acryloyl)phenyl)benzamide through the reversible inhibition of P-glycoprotein. Biochem. Biophys. Res. Commun., 355(1): 136-142.
50. Chen, D., S.H. Song, M.G. Wientjes, T.K. Yeh, L. Zhao, M. Villalona-Calero, G.A. Otterson, R. Jensen, M. Grever, A.J. Murgo and J.L. Au, 2006. Nontoxic suramin as a chemosensitizer in patients: Dosing nomogram development. Pharm. Res., 23(6): 1265-1274.
51. Frederiksen, L.J., R. Sullivan, L.R. Maxwell, S.K. Macdonald-Goodfellow, M.A. Adams, B.M. Bennett, D.R. Siemens and C.H. Graham, 2007. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin. Cancer Res., 13(7): 2199-2206.